Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in
Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation,
which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and
independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering
drugs that decrease mortality from cardiovascular disease and stroke. In addition, they
have anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower
C-reactive protein by the ability to reduce the production of interleukin (IL)-6, the
cytokine that activates the acute phase CRP response.
Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and
ET-1 in COPD patients.
- Medically optimized COPD patients
- Age 40-79 years.
- serum CRP levels >3mg/l
- Current smoker
- COPD exacerbation in the last 2 months.
- Active hepatic or severe renal dysfunction.
- connective tissue disease, chronic inflammatory disease, malignancy, any acute
illness, leukocytosis (>10,000 white blood cells) or thrombocytosis (>450,000
- Recent h/o myocardial infarction, angina in the last 6 months.